Bortezomib (Velcade)

Epidemiology

  • Indications: multiple myeloma, mantle cell lymphoma
    • In refractory or advancing multiple myeloma, complete clinical responses have been achieved

Pharmacology

  • Proteasome Inhibitor

Adverse Effects


References

  • xxx